Convatec notes CMS payment plans for skin substitutes in the United States

London, UK, 3 November 2025 – Convatec notes the Centers for Medicare & Medicaid Services (CMS) decision published on 31 October 2025 outlining their revised payment rate of $127.28 per sq cm with effect from 1 January 2026. This update follows Convatec's statement on 15 July 2025 regarding the CMS draft payment proposal. 

This CMS decision represents an estimated headwind in 2026 of approximately 1-2% of Group revenue, unchanged from the guidance given at our H1 25 results¹.

InnovaMatrix^® is a highly effective product with significant health benefits to patients and healthcare professionals. It has strong user feedback and clinical evidence, and we have recently submitted (October 2025) further real-world evidence (RWE) to CMS, in addition to RWE published in December 2024. Our randomised controlled trials continue to progress towards target publication in 2026.

We are confident of delivering long term profitable growth from InnovaMatrix^®, including developing sales and securing coverage across a range of indications, both within and outside the United States.

¹ Excluding the impact of any Local Coverage Determinations

About InnovaMatrix^® 
InnovaMatrix^® represented c.3% of Convatec sales in H1 2025. Convatec’s InnovaMatrix^® is a leading porcine placental-derived extra-cellular matrix for treatment of chronic, surgical and trauma wounds. The product is cleared by the US Food and Drug Administration (FDA) in 15 separate medical indications, based on an established predicate product, under a 510k medical device licence. Patients and HCPs have experienced first-hand the positive impact that InnovaMatrix^® products have on chronic wounds, including its potential to prevent amputation. 

Contacts 
Analysts & investors: ir@convatec.com  
Media: mediarelations@convatec.com 
 

About Convatec 

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com